NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions

NCT05540288

Status	RECRUITING
Phase	Phase 3
Sponsor	Nantes University Hospital
Enrollment	266 participants

Key Eligibility Criteria

Inclusion (13)

- Males and females e 18 years old
- Patient already in care or newly initiating care in Addictology departments for a behavioural addiction, diagnosed with current:
- Gambling disorder \[NORC DSM Screen for Gambling Problems (NODS), revised for DSM-5\]
- Food addiction \[Yale Food Addiction Scale (YFAS), revised for DSM-5\]
- Or Sexual addiction \[interview adapted from the NODS to explore the diagnostic criteria proposed by Carnes et al. (2012): NODS-SA\]

... and 8 more (see full listing online)

Exclusion (22)

- Being currently treated by another anti-craving drug that have been already tested for craving reduction in BAs (naltrexone, acamprosate, baclofène, topiramate, bupropion, N-acetyl-cystéine, disulfiram, etc.);
- Presenting a contraindication for the use of nalmefene (listed in the SmPC):
- Known hypersensitivity to the active substance or to any of the excipients. In particular, intolerance to galactose or deficiency in Lapp lactase or glucose-galactose malabsorption (rare hereditary diseases);
- Treatment by opioid agonists (full or partial) (opioid pain relievers, opioid substitution drugs);
- Recent history of opioid dependence or current opioid dependence;

... and 17 more (see full listing online)

Locations (13 total)

CHU de Besançon, Besançon, France
CHU de Bordeaux, Bordeaux, France
CHRU de Brest, Brest, France
... and 10 more locations